Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription


4 BMC Urol
2 Cancer
1 Cancer Res
2 Clin Cancer Res
1 Eur Radiol
2 Eur Urol
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
1 J Cell Physiol
1 J Clin Lab Anal
1 J Magn Reson Imaging
3 J Nucl Med
1 PLoS One
2 Prostate
1 Ther Adv Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Urol

  1. CANCINO-MARENTES ME, Hernandez-Flores G, Ortiz-Lazareno PC, Villasenor-Garcia MM, et al
    Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line.
    BMC Urol. 2021;21:38.
    PubMed         Abstract available

  2. LIU Y, Xu H, Wu B, Liu S, et al
    Small cell carcinoma of the bladder with coexisting prostate adenocarcinoma: two cases report and literature review.
    BMC Urol. 2020;20:134.
    PubMed         Abstract available

  3. THOMPSON JE, Sridhar AN, Shaw G, Rajan P, et al
    Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation.
    BMC Urol. 2020;20:81.
    PubMed         Abstract available

  4. HAMID ARAH, Kusuma Putra HW, Sari NP, Diana P, et al
    Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy.
    BMC Urol. 2020;20:71.
    PubMed         Abstract available


  5. WILKINS LJ, Tosoian JJ, Reichard CA, Sundi D, et al
    Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
    Cancer. 2021 Mar 15. doi: 10.1002/cncr.33419.
    PubMed         Abstract available

    Prostate cancer and the social construct of race.
    Cancer. 2021 Mar 15. doi: 10.1002/cncr.33417.

    Cancer Res

  7. WANG J, Wang J, Dai J, Jung Y, et al
    Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer.
    Cancer Res. 2021;81:1623.

    Clin Cancer Res

  8. FREEDLAND SJ, Allen J, Jarman A, Oyekunle T, et al
    Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Clin Cancer Res. 2021;27:1823.

  9. PALMBOS PL, Daignault-Newton S, Tomlins SA, Agarwal N, et al
    A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
    Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-21-0024.
    PubMed         Abstract available

    Eur Radiol

  10. KAN Y, Zhang Q, Hao J, Wang W, et al
    Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation.
    Eur Radiol. 2020;30:6274-6284.
    PubMed         Abstract available

    Eur Urol

    Re: Philip Cornford, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79:263-82.
    Eur Urol. 2021 Mar 9. pii: S0302-2838(21)00169.

  12. KWON DH, Booth CM, Prasad V
    Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    Eur Urol. 2021 Mar 12. pii: S0302-2838(21)00168.
    PubMed         Abstract available

    Int J Cancer

  13. HASAN MF, Ganapathy K, Sun J, Khatib A, et al
    LncRNA PAINT is Associated with Aggressive Prostate Cancer and Dysregulation of Cancer Hallmark Genes.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33569.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  14. YAMAZAKI H, Suzuki G, Aibe N, Yoshida K, et al
    Posterior Margins in Prostate Cancer Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:1657-1658.

  15. MITCHELL D, Jain S
    Brachytherapy Boost in Prostate Cancer: What Does Observational Data Add to the Debate?
    Int J Radiat Oncol Biol Phys. 2021;109:1230-1231.

    J Cell Physiol

  16. PAN HY, Mi YY, Xu K, Zhang Z, et al
    Association of C-reactive protein (CRP) rs1205 and rs2808630 variants and risk of cancer.
    J Cell Physiol. 2020;235:8571-8584.
    PubMed         Abstract available

    J Clin Lab Anal

  17. GARRIDO MM, Marta JC, Ribeiro RM, Pinheiro LC, et al
    Serum lipids and prostate cancer.
    J Clin Lab Anal. 2021 Mar 16:e23705. doi: 10.1002/jcla.23705.
    PubMed         Abstract available

    J Magn Reson Imaging

  18. KHOSRAVI P, Lysandrou M, Eljalby M, Li Q, et al
    A Deep Learning Approach to Diagnostic Classification of Prostate Cancer Using Pathology-Radiology Fusion.
    J Magn Reson Imaging. 2021 Mar 14. doi: 10.1002/jmri.27599.
    PubMed         Abstract available

    J Nucl Med

  19. FAROLFI A, Calderoni L, Mattana F, Mei R, et al
    Current and emerging clinical applications of PSMA-PET diagnostic imaging for prostate cancer.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.257238. doi: 10.2967/jnumed.120.257238.
    PubMed         Abstract available

  20. UPRIMNY C, Bayerschmidt S, Kroiss AS, Fritz J, et al
    Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for (68)Ga-PSMA-11 PET/CT.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.261866. doi: 10.2967/jnumed.120.261866.
    PubMed         Abstract available

  21. RAUSCHER I, Karimzadeh A, Schiller K, Horn T, et al
    Detection efficacy of (18)F-rhPSMA-7.3 PET/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment.
    J Nucl Med. 2021 Mar 12. pii: jnumed.120.260091. doi: 10.2967/jnumed.120.260091.
    PubMed         Abstract available

    PLoS One

  22. FALLARA G, Lissbrant IF, Styrke J, Montorsi F, et al
    Observational study on time on treatment with abiraterone and enzalutamide.
    PLoS One. 2020;15:e0244462.
    PubMed         Abstract available


  23. LIOTTI A, La Civita E, Cennamo M, Crocetto F, et al
    Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24117.
    PubMed         Abstract available

  24. LEHTO TK, Sturenberg C, Malen A, Erickson AM, et al
    Transcript analysis of commercial prostate cancer risk stratification panels in hard-to-predict grade group 2-4 prostate cancers.
    Prostate. 2021 Mar 18. doi: 10.1002/pros.24108.
    PubMed         Abstract available

    Ther Adv Urol

  25. SALTMAN A, Zegar J, Haj-Hamed M, Verma S, et al
    Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?
    Ther Adv Urol. 2021;13:1756287221997186.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.